- Home
- GDTC
as 10-17-2024 4:00pm EST
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
| Founded: | 2018 | Country: | Singapore |
| Employees: | N/A | City: | N/A |
| Market Cap: | 23.7M | IPO Year: | 2023 |
| Target Price: | $5.00 | AVG Volume (30 days): | 12.4K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.20 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.20 - $5.50 | Next Earning Date: | 01-01-0001 |
| Revenue: | $330,254 | Revenue Growth: | -21.95% |
| Revenue Growth (this year): | 4.46% | Revenue Growth (next year): | N/A |
Latest CytoMed Therapeutics Limited News
GDTC Breaking Stock News: Dive into GDTC Ticker-Specific Updates for Smart Investing
GlobeNewswire
11 days ago
CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant
TipRanks
14 days ago
CytoMed Acquires Cord Blood Assets, Eyes Regenerative Medicine
GlobeNewswire
15 days ago
CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank
GlobeNewswire
18 days ago
CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates
GlobeNewswire
23 days ago
Presenting on the Emerging Growth Conference 75 Day 2 on September 26
GlobeNewswire
2 months ago
Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now
GlobeNewswire
3 months ago
CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers
GlobeNewswire
3 months ago
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now
Compare GDTC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GDTC CytoMed Therapeutics Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.